Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million ...
Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading this week, for the March 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds. On November 1, TD Cowen analyst Brendan Smith touted the progress the company has made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results